Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (NCT02650401)
A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, Phase 1/2 multicenter dose escalation study in pediatric patients with relapsed or refractory extracranial solid tumors (Phase 1), with additional expansion cohorts (Phase 2) in patients with primary brain tumors harboring NTRK1/2/3 or ROS1 gene fusions, and extracranial solid tumors harboring NTRK1/2/3 or ROS1 gene fusions.
Who can join: Review the eligibility criteria below.
Location: University of California San Diego — La Jolla, California
Age range: 0 Years to 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- University of California San Diego — La Jolla, California
- UCSF Benioff Children's Hospital — San Francisco, California
- Children's Hospital Colorado — Aurora, Colorado
- Egleston Children's Hospital at Emory University Atlanta — Atlanta, Georgia
- University of Chicago — Chicago, Illinois
- Johns Hopkins University — Baltimore, Maryland
- Dana Farber Cancer Institute — Boston, Massachusetts
- Washington University,St. Louis Children's Hospital — St Louis, Missouri
- Memorial Sloan Kettering Cancer Center — New York, New York
- Nationwide Children's Hospital — Columbus, Ohio
- Oregon Health & Science Uni — Portland, Oregon
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- St. Jude Children'S Research Hospital — Memphis, Tennessee
- Texas Children's Cancer and Hematology Center — Houston, Texas
- Primary Children's Hospital — Salt Lake City, Utah
- The Hospital for Sick Children — Toronto, Ontario
- Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine — Shanghai, Shanghai Municipality
- Beijing Children's Hospital, Capital Medical University — Beijing,
- Centre Leon Berard — Lyon,
- Hôpital de la Timone, Oncologie Pédiatrique — Marseille,
- Universitaetsklinikum Heidelberg — Heidelberg, Baden-Wurttemberg
- Hong Kong Children's Hospital — Hong Kong,
- Fondazione IRCCS Istituto Nazionale dei Tumori — Milan, Lombardy
- Hospital Infantil Universitario Nino Jesus — Madrid,
- Royal Marsden Hospital (Sutton) — London,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumors
- Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors — Basking Ridge, New Jersey
- Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours — Edmonton, Alberta
- Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) — Santa Monica, California
- A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial — Porto Alegre, Rio Grande do Sul
- Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors — Los Angeles, California
- Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors — Phoenix, Arizona
Explore by condition: All Solid Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.